Granted Patent
B2
US 12,303,718 · App. 17/479,873 · Granted May 20, 2025
Graphical representation of radiation therapy
Inventors:
Michael Kirk Owens (San Francisco, CA); Peter Demetri Olcott (Los Gatos, CA); Rostem Bassalow (Lacey, WA)
Assignee:
RefleXion Medical, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are methods for monitoring the radiation delivery during a radiotherapy delivery session and providing a graphical representation of radiation delivery to an operator (e.g., a clinician, a medical physicist, a radiation therapy technologist). The graphics are updated in real-time, as radiation data is collected by the radiotherapy system, and in some variations, can be updated every 15 minutes or less. A variety of graphical representations (“graphics”) can be used to indicate the status of radiation delivery relative to the planned radiation delivery. Methods optionally include calculating a range of acceptable metric values, generating graphics that represent the range of acceptable metrics values, and generating a graphic that depicts the real-time values of those metrics overlaid with the range of acceptable metrics values.
Claims (21)
1. A method for monitoring radiotherapy, the method comprising:
(a) detecting acquiring PET imaging data of a target region using one or more PET detectors during the delivery of while delivering radiation for during a radiotherapy treatment session;
(b) calculating a dosimetric objective value using the acquired PET imaging data, wherein the dosimetric objective value represents a delivered radiation dose;
(c) comparing the dosimetric objective value with a range of acceptable dosimetric objective values for the radiotherapy treatment session; and
(d) generating a notification that indicates whether the dosimetric objective value is within the range of acceptable dosimetric objective values.
2. The method of claim 1 , further comprising pausing radiation delivery in the treatment session if the dosimetric objective value is outside the range of acceptable dosimetric objective values.
3. The method of claim 1 , wherein the dosimetric objective value comprises one or more of a minimum percent volume at a selected dose level, prescription dose, maximum absolute volume at a selected dose level, and maximum percent volume at a selected dose level.
4. The method of claim 1 , wherein calculating the dosimetric objective value further comprises calculating a plan quality index (PQI).
5. The method of claim 4 , wherein the PQI comprises one or more of the following: mean dose levels over the target region, volumetric coverage of a 95% or 100 % dose level reference over the target region, and/or a maximum dose level in an organ-at-risk (OAR).
6. The method of claim 1 , wherein calculating the dosimetric objective value further comprises calculating a dose volume histogram (DVH) curve for the target region, wherein the range of acceptable dosimetric objective values is represented by bounded DVH curves comprising an upper bound curve and a lower bound curve, and comparing the dosimetric objective value with the range of acceptable dosimetric objective values comprises comparing the calculated DVH curve with the bounded DVH curves for the target region.
7. The method of claim 1 , wherein (a)-(d) are performed at predetermined timepoints during the delivery of radiation.
8. The method of claim 7 , wherein the predetermined timepoints are absolute timepoints during the delivery of radiation.
9. The method of claim 7 , wherein the predetermined timepoints are relative timepoints that are proportions of the total treatment session duration.
10. The method of claim 7 , wherein the predetermined timepoints are defined by the number of radiation pulses emitted by a therapeutic radiation source.
11. The method of claim 1 , wherein generating a notification comprises displaying a checkpoint status indicator as to whether the dosimetric objective value is within the range of acceptable dosimetric objective values.
12. The method of claim 11 , wherein the checkpoint status indicator displays “PASS” when the dosimetric objective value is within the range of acceptable dosimetric objective values, and the checkpoint status indicator displays “FAIL” when the dosimetric objective value is outside the range of acceptable dosimetric objective values.
13. The method of claim 2 , wherein pausing radiation delivery in the treatment session further comprises generating a command signal that deactivates a therapeutic radiation source.
14. The method of claim 2 , wherein pausing radiation delivery in the treatment session further comprises generating a command signal that closes at least one leaf of a multi-leaf collimator.
15. The method of claim 2 , wherein pausing radiation delivery in the treatment session further comprises generating a command signal that stops gantry motion.
16. The method of claim 11 , wherein comparing the dosimetric objective value with a range of acceptable dosimetric objective values further comprises updating the checkpoint status indicator to display “ACTIVE” during the comparison.
17. The method of claim 11 , wherein the checkpoint status indicator displays “WARNING” when the dosimetric objective value is within a tolerance level of an upper and/or lower bounds of the range of acceptable dosimetric objective values.
Assignments (2)
SECURITY INTEREST
Recorded Jul 11, 2022
From: REFLEXION MEDICAL, INC.
To: OXFORD FINANCE LLC
Reel/Frame 060619/0066 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 21, 2021
From: OWENS, MICHAEL KIRK; OLCOTT, PETER DEMETRI; BASSALOW, ROSTEM
To: REFLEXION MEDICAL, INC.
Reel/Frame 057543/0715 →
Continuity (4)
Provisional Application
62537422
· Jul 26, 2017
References Cited (294)
US 3794840A
· Scott
· 1974
[cited by applicant]
US 6385286B1
· Fitchard et al.
· 2002
[cited by applicant]
US 6438202B1
· Olivera et al.
· 2002
[cited by applicant]
US 6618467B1
· Ruchala et al.
· 2003
[cited by applicant]
US 6810108B2
· Clark et al.
· 2004
[cited by applicant]
US 7265356B2
· Pelizzari et al.
· 2007
[cited by applicant]
US 7280633B2
· Cheng et al.
· 2007
[cited by applicant]
US 7302033B2
· Carrano et al.
· 2007
[cited by applicant]
US 7379531B2
· Esham et al.
· 2008
[cited by applicant]
US 7412029B2
· Myles
· 2008
[cited by applicant]
US 7412280B2
· Hertel et al.
· 2008
[cited by applicant]
US 7446328B2
· Rigney et al.
· 2008
[cited by applicant]
US 7469035B2
· Keall et al.
· 2008
[cited by applicant]
US 7522779B2
· Fu et al.
· 2009
[cited by applicant]
US 7623623B2
· Raanes et al.
· 2009
[cited by applicant]
US 7639853B2
· Olivera et al.
· 2009
[cited by applicant]
US 7831289B2
· Riker et al.
· 2010
[cited by applicant]
US 7839972B2
· Ruchala et al.
· 2010
[cited by applicant]
US 7906770B2
· Otto
· 2011
[cited by applicant]
US 7945021B2
· Shapiro et al.
· 2011
[cited by applicant]
US 7983380B2
· Guertin et al.
· 2011
[cited by applicant]
US 8019042B2
· Shukla et al.
· 2011
[cited by applicant]
US 8063376B2
· Maniawski et al.
· 2011
[cited by applicant]
US 8086004B2
· Kuduvalli et al.
· 2011
[cited by applicant]
US 8090074B2
· Filiberti et al.
· 2012
[cited by applicant]
US 8107589B2
· Sakurai et al.
· 2012
[cited by applicant]
US 8144962B2
· Busch et al.
· 2012
[cited by applicant]
US 8149991B2
· Moreau
· 2012
[cited by applicant]
US 8269195B2
· Rigney et al.
· 2012
[cited by applicant]
US 8278633B2
· Nord et al.
· 2012
[cited by applicant]
US 8295430B2
· Zhu et al.
· 2012
[cited by applicant]
US 8331532B2
· Nord et al.
· 2012
[cited by applicant]
US 8406844B2
· Ruchala et al.
· 2013
[cited by applicant]
US 8442287B2
· Fordyce, II et al.
· 2013
[cited by applicant]
US 8457372B2
· Fu et al.
· 2013
[cited by applicant]
US 8467497B2
· Lu et al.
· 2013
[cited by applicant]
US 8483803B2
· Partain et al.
· 2013
[cited by applicant]
US 8509383B2
· Lu et al.
· 2013
[cited by applicant]
US 8536547B2
· Maurer, Jr. et al.
· 2013
[cited by applicant]
US 8554573B2
· Pekar et al.
· 2013
[cited by applicant]
US 8559596B2
· Thomson et al.
· 2013
[cited by applicant]
US 8588367B2
· Busch et al.
· 2013
[cited by applicant]
US 8605857B1
· Renner
· 2013
[cited by applicant]
US 8681938B2
· Myles
· 2014
[cited by applicant]
US 8767917B2
· Ruchala et al.
· 2014
[cited by applicant]
US 8816307B2
· Kuusela et al.
· 2014
[cited by applicant]
US 8824630B2
· Maurer, Jr. et al.
· 2014
[cited by applicant]
US 8831706B2
· Fu et al.
· 2014
[cited by applicant]
US 8836697B2
· Nord et al.
· 2014
[cited by applicant]
US 8861672B2
· Maltz et al.
· 2014
[cited by applicant]
US 8874187B2
· Thomson et al.
· 2014
[cited by applicant]
US 8917813B2
· Maurer, Jr. et al.
· 2014
[cited by applicant]
US 9019307B1
· Grimm
· 2015
[cited by applicant]
US 9155909B2
· Ishikawa
· 2015
[cited by applicant]
US 9437340B2
· Echner et al.
· 2016
[cited by applicant]
US 9498167B2
· Mostafavi et al.
· 2016
[cited by applicant]
US 9539441B2
· Lane et al.
· 2017
[cited by applicant]
US 9616251B2
· Filiberti et al.
· 2017
[cited by applicant]
US 9849308B2
· Berlinger et al.
· 2017
[cited by applicant]
US 9956429B2
· Holmes et al.
· 2018
[cited by applicant]
US 9974494B2
· Mostafavi et al.
· 2018
[cited by applicant]
US 9987504B2
· Nord et al.
· 2018
[cited by applicant]
US 9990711B2
· Lugosi et al.
· 2018
[cited by applicant]
US 20040122308A1
· Ding
· 2004
[cited by applicant]
US 20050207531A1
· Dempsey et al.
· 2005
[cited by applicant]
US 20120292534A1
· Geneser et al.
· 2012
[cited by applicant]
US 20150367143A1
· Muraki et al.
· 2015
[cited by applicant]
US 20240316363A1
· Voronenko et al.
· 2024
[cited by applicant]
CN 1824342A
· 2006
[cited by applicant]
CN 101267767A
· 2008
[cited by applicant]
CN 101489477A
· 2009
[cited by applicant]
CN 101496018A
· 2009
[cited by applicant]
CN 102068763A
· 2011
[cited by applicant]
CN 102641561A
· 2012
[cited by applicant]
CN 103180014A
· 2013
[cited by applicant]
CN 103209736A
· 2013
[cited by applicant]
CN 103845068A
· 2014
[cited by applicant]
CN 104284697A
· 2015
[cited by applicant]
CN 105658279A
· 2016
[cited by applicant]
CN 106563211A
· 2017
[cited by applicant]
CN 107072595A
· 2017
[cited by applicant]
CN 107072628A
· 2017
[cited by applicant]
EP 2072081A1
· 2009
[cited by applicant]
EP 1501604B1
· 2009
[cited by applicant]
EP 1898234B1
· 2010
[cited by applicant]
EP 2904974A1
· 2015
[cited by applicant]
EP 2990078A1
· 2016
[cited by applicant]
EP 2874702B1
· 2016
[cited by applicant]
JP 2009160308A
· 2009
[cited by applicant]
JP 2009538195A
· 2009
[cited by applicant]
JP 2012035072A
· 2012
[cited by applicant]
JP 2012506734A
· 2012
[cited by applicant]
JP 2013059576A
· 2013
[cited by applicant]
JP 2014023741A
· 2014
[cited by applicant]
JP 2014503315A
· 2014
[cited by applicant]
JP 2016055161A
· 2016
[cited by applicant]
JP 2016168077A
· 2016
[cited by applicant]
WO WO0059576A1
· 2000
[cited by applicant]
WO WO2007082126A2
· 2007
[cited by applicant]
WO WO2007082126A3
· 2007
[cited by applicant]
WO WO2008011725A1
· 2008
[cited by applicant]
WO WO2008013598A2
· 2008
[cited by applicant]
WO WO2008013598A3
· 2008
[cited by applicant]
WO WO2013024380A1
· 2013
[cited by applicant]
WO WO2013054788A1
· 2013
[cited by applicant]
WO WO2013093852A1
· 2013
[cited by applicant]
WO WO2016023786A1
· 2016
[cited by applicant]
WO WO2016064750A1
· 2016
[cited by applicant]
WO WO2017081768A1
· 2017
[cited by applicant]
WO WO2018183748A1
· 2018
[cited by applicant]
WO WO2018222751A1
· 2018
[cited by applicant]
WO WO2018237328A1
· 2018
[cited by applicant]
WO WO2019160958A1
· 2019
[cited by applicant]
Adaptive Radiation Therapy: ISBN:9781439816356. 2011. CRC Press. X Allen Li (Ed.): 426 pages (cover only); URL: https://www.google.com/books/edition/Adaptive_Radiation_Therapy/9hEPvAlgPfMC (accessed Aug. 31, 2021).
[cited by applicant]
Akpati, H.C. et al. (2008). “Unified dosimetry index (UDI): A figure of merit for ranking treatment plans,” J Appl Clin Med Phys. 9:99-108.
[cited by applicant]
Alrowaili, Z.A. et al. (2015). “2D mapping of the MV photon fluence and 3D dose reconstruction in real itime for quality assurance during radiotherapy treatment,” J. Instrumentation IOP Science 10:P09019, 17 total pages.
[cited by applicant]
ArcCHECK® & 3DVH (2016). Sun Nuclear, located at https://www.sunnuclear.com/solutions/patientqa/arccheck3dvh, retrieved on Jul. 31, 2019, 12 total pages.
[cited by applicant]
Chang, J.Y. et al. (2008). “Image-guided radiation therapy for non-small cell lung cancer,” J. Thorac Oncol. 3:177-186 (Abstract Only).
[cited by applicant]
Chen, Q. et al. (2016). “SU-D-201-03: During-Treatment Delivery Monitoring System for TomoTherapy,” Med. Phys. 43:3334, 1 total page.
[cited by applicant]
Chen, Q. (2016) “During treatment delivery monitoring system for tomotherapy,” Presentation, University of Virginia Health System, 16 total pages.
[cited by applicant]
Chen, X. et al. (2012). “Smoothing proximal gradient method for general structured sparse regression,” The Annals of Applied Statistics 6:719-752.
[cited by applicant]
Croteau, E. et al. (2016). “PET Metabolic Biomarkers for Cancer,” Biomark Cancer. 8(Suppl 2):61-69.
[cited by applicant]
Dieterich, S. et al. (2003). “Skin respiratory motion tracking for stereotactic radiosurgery using the CyberKnife,”
[cited by applicant]
ECN Magazine (2016). “Magic plate radiation detector helps improve cancer radiotherapy,” located at https://www.ecnmag.com/news/2016/03/magic-plate-radiation-detector-helps-improve-cancer-radiotherapy, retrieved on Jul.…
[cited by applicant]
Extended European Search Report mailed on Feb. 3, 2021, for EP Application No. 18 810 297.4, filed on May 30, 2018, 4 pages.
[cited by applicant]
Extended European Search Report mailed on Mar. 15, 2021, for EP Application No. 18 837.615.6, filed on Jul. 26, 2018, 8 pages.
[cited by applicant]
Extended European Search Report mailed on Jun. 14, 2021, for EP Application No. 18 821 003.3, filed on Jun. 22, 2018, 5 pages.
[cited by applicant]
Fan, Q. et al. (2013). “Toward a Planning Scheme for Emission Guided Radiation Therapy (EGRT): FDG Based Tumor Tracking in a Metastatic Breast Cancer Patient,”
[cited by applicant]
Fan, Q. et al. (2012). “Emission Guided Radiation Therapy for Lung and Prostrate Cancers: A Feasibility Study on a Digital Patient,”
[cited by applicant]
Final Office Action mailed on Jul. 14, 2021, for U.S. Appl. No. 16/582,308, filed Sep. 25, 2019, 8 pages.
[cited by applicant]
Final Office Action mailed on May 18, 2022, for U.S. Appl. No. 16/016,272, filed Jun. 22, 2018, 31 pages.
[cited by applicant]
Final Office Action mailed on Sep. 15, 2022, for U.S. Appl. No. 16/582,308, filed Sep. 25, 2019, 10 pages.
[cited by applicant]
Fredriksson (2013). “Robust optimization of radiation therapy accounting for geometric uncertainty,” KTH Engin. Sciences, pp. 8-14.
[cited by applicant]
Gibbons, J.P. (2004). “Dose calculation and verification for tomotherapy,” 2004 ACMP Meeting, Scottsdale, AZ., 71 total pages.
[cited by applicant]
Handsfield, L.L. et al. (2014). “Phantomless patient-specific TomoTherapy QA via delivery performance monitoring and a secondary Monte Carlo dose calculation,”
[cited by applicant]
Hoeben, B.A.W. et al. (2013). “Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer,” Acta Oncologica 52:1257-1271.
[cited by applicant]
Hunt, M.A. et al. (2003). “Treatment Planning Considerations using IMRT,” pp. 103-121.
[cited by applicant]
International Search Report mailed on Nov. 16, 2018, for PCT Application No. PCT/US2018/039104, filed on Jun. 22, 2018, 4 pages.
[cited by applicant]
International Search Report mailed on Oct. 3, 2018, for PCT Application No. PCT/US2018/035188, filed on May 30, 2018, 4 pages.
[cited by applicant]
International Search Report mailed on Oct. 3, 2018, for PCT Application No. PCT/US2018/043954, filed on Jul. 26, 2018, 3 pages.
[cited by applicant]
International Search Report mailed on Apr. 23, 2020, for PCT Application No. PCT/US2020/013927, filed on Jan. 16, 2020, 3 pages.
[cited by applicant]
International Search Report mailed on Dec. 1, 2020, for PCT Application No. PCT/US2020/040774, filed on Jul. 2, 2020, 4 pages.
[cited by applicant]
Kak, A. et al. (1988). “Aliasing artifacts and noise in CT images,” Principles of computerized tomographic imaging, pp. 177-201.
[cited by applicant]
Kapatoes, J.M. et al. (2001). “A feasible method for clinical delivery verification and dose reconstruction in tomotherapy,”
[cited by applicant]
Kapatoes, J. M. (2001). “On the accuracy and effectiveness of dose reconstruction for tomotherapy,”
[cited by applicant]
Keall, P.J. et al. (2001). “Motion adaptive x-ray therapy: a feasibility study,”
[cited by applicant]
Kim et al. “18F-FDG PET/CT of Advanced Gastric Carcinoma and Association of H ER2 Expression with Standardized Uptake Value.” Asia Oceania J Nucl Med Biol, 2014; 2(1): 12-18.
[cited by applicant]
Kong et al. “Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer.” JAMA Oncol. Oct. 2017; 3(10): 1358-1365. Published online …
[cited by applicant]
Lu, W. (2008). “Real-time motion-adaptive delivery (MAD) using binary MLC: I. Static beam (topotherapy) delivery,” Phys. Med. Biol. 53:6491-6511.
[cited by applicant]
Lu, W. (2009). “Real-time motion-adaptive-optimization (MAO) in tomotherapy,” Phys. Med. Biol. 54:4373-4398.
[cited by applicant]
Mackie, T.R. et al. (1993). “Tomotherapy: A new concept for the delivery of dynamic conformal radiotherapy,” Med. Phys. 20:1709-1719.
[cited by applicant]
Mazin, S.R. et al. (2010). “Emission-guided radiation therapy: Biologic targeting and adaptive treatment,” Am. College of Radiology, pp. 989-990.
[cited by applicant]
McMahon, R. et al. (2008). “A real-time dynamic-MLC control algorithm for delivering IMRT to targets undergoing 2D rigid motion in the beam's eye view,” Med. Phys. 35:3875-3888.
[cited by applicant]
Non-Final Office Action mailed on Dec. 6, 2019, for U.S. Appl. No. 15/993,325, filed May 30, 2018, 8 pages.
[cited by applicant]
Non-Final Office Action mailed on Dec. 22, 2020, for U.S. Appl. No. 16/554,258, filed Aug. 28, 2019, 11 pages.
[cited by applicant]
Non-Final Office Action mailed on Feb. 11, 2021, for U.S. Appl. No. 16/582,308, filed Sep. 25, 2019, 9 pages.
[cited by applicant]
Non-Final Office Action mailed on Sep. 21, 2021, for U.S. Appl. No. 16/016,272, filed Jun. 22, 2018, 34 pages,.
[cited by applicant]
Non-Final Office Action mailed on Jun. 8, 2022, for U.S. Appl. No. 16/582,308, filed Sep. 25, 2019, 9 pages.
[cited by applicant]
Non-Final Office Action mailed on Aug. 30, 2022, for U.S. Appl. No. 17/235,812, filed Apr. 20, 2021, 8 pages.
[cited by applicant]
Notice of Allowance mailed on Jul. 25, 2019, for U.S. Appl. No. 16/046,746, filed Jul. 26, 2018, 8 pages.
[cited by applicant]
Notice of Allowance mailed on Aug. 15, 2019, for U.S. Appl. No. 16/046,746, filed Jul. 26, 2018, 7 pages.
[cited by applicant]
Notice of Allowance mailed on Apr. 20, 2020, for U.S. Appl. No. 15/993,325, filed May 30, 2018, 7 pages.
[cited by applicant]
Olivera, G.H. et al. (2000). “Modifying a plan delivery without re-optimization to account for patient offset in tomotherapy,” Proceedings of the 22
[cited by applicant]
Papanikolaou, N. et al. (2010). “MU-Tomo: Independent dose validation software for helical tomo therapy,”
[cited by applicant]
Parodi, K. (2015). “Vision 20/20: Positron emission tomography in radiation therapy planning, delivery and monitoring,” Am. Assoc. Phys. Med. 42:7153-7168.
[cited by applicant]
Pyakuryal, A. et al. (2010). “A computational tool for the efficient analysis of dose-volume histograms for radiation therapy treatment plans,” J Appl. Clin. Med. Phys. 11:137-157.
[cited by applicant]
Rahmim, A. et al. (2009). “Four-dimensional (4d) image reconstruction strategies in dynamic pet: beyond conventional independent frame reconstruction,” Medical physics 36:3654-3670.
[cited by applicant]
Reader, A.J. et al. (2007). “Advances in pet image reconstruction,” PET clinics 2:173-190.
[cited by applicant]
Riederer, S.J. et al. (1978). “The noise power spectrum in computed x-ray tomography,” Physics in medicine and biology 23:446.
[cited by applicant]
ScandiDos (2019). Delta
[cited by applicant]
Seppenwoolde, Y. et al. (2002). “Precise and real-time measurement of 3d tumor motion in lung due to breathing and heartbeat, measured during radiotherapy,” International Journal of Radiation Oncology Biology Physics 53…
[cited by applicant]
Thorek, D. “Positron lymphography: multimodal, high-resolution, dynamic mapping and resection of lymph nodes after X intradermal injection of 18F-FDG.” J Nucl Med. Sep. 2012;53(9):1438-45.
[cited by applicant]
Thorwarth, D. et al. (2010). “Physical radiotherapy treatment planning based on functional PET/CT data,” Radiotherapy Oncology, pp. 317-324.
[cited by applicant]
Tuncel, N. “Adaptive radiotherapy from past to future frontiers.” International Journal of Radiology & Radiation Therapy 2021; 8(2):81-84.
[cited by applicant]
Varian Medical Systems (2019). MOBIUS3D, Varian oncology software products, located at https://www.varian.com/oncology/products/software/mobius3d, retrieved on Jul. 31, 2019, 3 total pages.
[cited by applicant]
Written Opinion of the International Searching Authority mailed on Nov. 16, 2018, for PCT Application No. PCT/US2018/039104, filed on Jun. 22, 2018, 6 pages.
[cited by applicant]
Written Opinion of the International Searching Authority mailed on Oct. 3, 2018, for PCT Application No. PCT/US2018/035188, filed on May 30, 2018, 28 pages.
[cited by applicant]
Written Opinion of the International Searching Authority mailed on Oct. 3, 2018, for PCT Application No. PCT/US2018/043954, filed on Jul. 26, 2018, 5 pages.
[cited by applicant]
Written Opinion of the International Searching Authority mailed on Apr. 23, 2020, for PCT Application No. PCT/US2020/013927, filed on Jan. 16, 2020, 4 pages.
[cited by applicant]
Written Opinion of the International Searching Authority mailed on Dec. 1, 2020, for PCT Application No. PCT/US2020/040774, filed on Jul. 2, 2020, 8 pages.
[cited by applicant]
Written Opinion of the International Searching Authority mailed on Jun. 27, 2017, for PCT Patent Application No. PCT/US2017/021647, filed on Mar. 9, 2017, 5 pages.
[cited by applicant]
Yan, D. et al. (1997). “Adaptive radiation therapy,”
[cited by applicant]
Zhang, H. et al. (2002). Progress in the Physics of Tumor Radiation Therapy, Beijing Medical University, China Union Medical University Joint Press, p. 164 (with English translation).
[cited by applicant]
Zhao, H. et al. (2015). Practical Imaging Diagnosis, University Press, Aug. 2015, p. 167 (with English translation).
[cited by applicant]
Corrected Notice of Allowability mailed on Mar. 13, 2023, for U.S. Appl. No. 17/235,812, filed Apr. 20, 2021, 4 pages.
[cited by applicant]
Extended European Search Report mailed on Jun. 23, 2023, for EP Application No. 20 840 804.7, filed on Jul. 2, 2020, 7 pages.
[cited by applicant]
Guohua H. et al. (Nov. 2002). “Chapter 8: Radionuclide diagnosis and treatment,” in
[cited by applicant]
Hongsheng, S. (Aug. 2015). “Chapter 8: Nuclear medicine imaging,” in
[cited by applicant]
Non-Final Office Action mailed on Nov. 21, 2022, for U.S. Appl. No. 16/016,272, filed Jun. 22, 2018, 27 pages.
[cited by applicant]
Notice of Allowance mailed on Feb. 1, 2023, for U.S. Appl. No. 17/235,812, filed Apr. 20, 2021, 7 pages.
[cited by applicant]
Notice of Allowance mailed on Mar. 9, 2023, for U.S. Appl. No. 16/016,272, filed Jun. 22, 2018, 8 pages.
[cited by applicant]
Notice of Allowance mailed on Dec. 13, 2023, for U.S. Appl. No. 17/375,586, filed Jul. 14, 2021, 12 pages.
[cited by applicant]
Peng, C. et al. (Jun. 2016). “Chapter 15: Clinical radiotherapy technique,” in
[cited by applicant]
Shiying, Y. (Jul. 2009). “Chapter 4: Design of radiotherapy plan,” in
[cited by applicant]
Xuening, Z. (Dec. 2010). “Chapter 2: Principles and Stereotactic Techniques of LEKSELL Gamma Knife,” in
[cited by applicant]
Zhiliao, Z. et al. (Mar. 2002). “Progress in Physics of Tumor Radiotherapy,” Beijing Medical University and China Union Medical University Joint Publishing House, first edition, first printing, pp. 163-164 (with English…
[cited by applicant]
Extended European Search Report mailed on May 31, 2024, for EP Application No. 23 211 269.8, filed on Jun. 22, 2018, 5 pages.
[cited by applicant]
Geets, X. et al. (Oct. 2007). “Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy…
[cited by applicant]
Non-Final Office Action mailed on Jun. 24, 2024, for U.S. Appl. No. 18/295,448, filed Apr. 4, 2023, 8 pages.
[cited by applicant]
Notice of Allowance mailed on May 9, 2024, for U.S. Appl. No. 17/571,273, filed Jan. 7, 2022, 15 pages.
[cited by applicant]
Notice of Allowance mailed on Sep. 29, 2024, for U.S. Appl. No. 18/295,448, filed Apr. 4, 2023, 5 pages.
[cited by applicant]
Supplemental Notice of Allowability mailed on Aug. 8, 2024, for U.S. Appl. No. 17/571,273, filed Jan. 7, 2022, 2 pages.
[cited by applicant]
Cited By (4)